Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mianserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 8/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 7/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.97 |
| ▸ | HTR2B known ✓ | P41595 | 5/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 0.97 |
| ▸ | HTR1D known ✓ | P28221 | 3/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 3/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.97 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.97 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.97 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mianserin SCHEMBL340474 | 1.00 | MEN1 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL29182002 | 0.99 | MEN1 (0.97) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL18020 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL353397 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL9122085 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL23326358 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL29356897 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL8344416 | 0.97 | DRD3 (0.97) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL11336834 | 0.97 | HTR2A (0.97) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL9752060 | 0.97 | DRD3 (0.97) | MEN1TP53CYP3A4KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097115-A1 | IMMUNOGENIC COMPOSITIONS AND USE THEREOF | BROAD INST INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12545710-B2 | Multiple antigen presenting immunogenic composition, and methods and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-12514915-B2 | Vaccines and related methods for treatment of Pseudomonas bacterial infections | MARSHALL UNIVERSITY RESEARCH CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4665387-A2 | TRYPTOPHAN NEOANTIGEN PEPTIDES FOR DIAGNOSTICS, THERAPEUTICS, AND VACCINES | Calviri, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12419948-B2 | Immunogenic compositions and use thereof | THE BROAD INSTITUTE, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3658179-B1 | METHODS AND COMPOSITIONS FOR HETEROLOGOUS REPRNA IMMUNIZATIONS | JANSSEN VACCINES & PREVENTION BV (NL) | 2025-09-17 | — | — | EP | disclosed |
| US-12370246-B2 | Immunogens and methods for discovery and screening thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250228923-A1 | COMBINED VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250188135-A1 | A MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE COMPRISING B- AND T-CELL ANTIGENS, IMMUNOGENIC COMPOSITION, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12275766-B2 | Neoantigen peptide mimics | JANSSEN BIOTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20220118081-A1 | HIV vaccine regimens | JANSSEN VACCINES & PREVENTION BV (NL) | 2022-04-21 | — | — | US | disclosed |
| US-11305001-B2 | Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220111033-A1 | Methods and Compositions for Heterologous repRNA Immunizations | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-04-14 | — | — | US | disclosed |
| US-20220096622-A1 | Compositions and Methods for Inducing Protective Immunity Against Human Immunodeficiency Virus Infection | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2022-03-31 | — | — | US | disclosed |
| US-20220088172-A1 | Poxvirus Vectors Encoding HIV Antigens, and Methods of Use Thereof | BAVARIAN NORDIC A/S (DK) | 2022-03-24 | — | — | US | disclosed |
| US-20220088180-A1 | IMMUNOGENIC COMPOSITIONS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | disclosed |
| EP-3964569-A1 | HUMAN IMMUNODEFICIENCY VIRUS ANTIGENS, VECTORS, COMPOSITIONS, AND METHODS OF USE THEREOF | Janssen Vaccines & Prevention B.V. (NL) | 2022-03-09 | — | — | EP | disclosed |
| US-20220064669-A1 | CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES | SABIN VACCINE INSTITUTE | 2022-03-03 | — | — | US | disclosed |
| CN-114015066-A | Covalent organic framework materials, methods of making and uses thereof | 北京大学 | 2022-02-08 | — | — | CN | disclosed |
| US-11235047-B2 | Immunogens and methods for discovery and screening thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545710-B2 | Multiple antigen presenting immunogenic composition, and methods and uses thereof | CD14, HLA-DRB1, MICA | DRD3 4157/4885HTR2A 4647/4885DRD2 4477/4885 |
| US-11305001-B2 | Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof | CD14, TLR8, SPAG5 | DRD3 3891/4885HTR2A 3927/4885DRD2 4673/4885 |
| US-20260097115-A1 | IMMUNOGENIC COMPOSITIONS AND USE THEREOF | HLA-DRB1, MICA, HLA-B | DRD3 2420/4885HTR2A 1469/4885DRD2 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.